Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Summary: Background: The importance of primary biliary cholangitis as an indication for liver transplantation has probably been influenced by the introduction of therapies, and changes in selection criteria and disease epidemiology. Aims: To assess the time trends in liver transplantation for primary biliary cholangitis and to evaluate the characteristics of the patient population during the past three decades. Methods: Patients undergoing liver transplantation from 1986 to 2015 in centres reporting to the European Liver Transplantation Registry were included. We excluded combined organ transplantations and patients <18 years. Trends were assessed using linear regression models. Results: We included 112 874 patients, of whom 6029 (5.3%) had primary biliary cholangitis. After an initial increase in the first decade, the annual number of liver transplantation for primary biliary cholangitis remained stable at around 200. The proportion of liver transplantations for primary biliary cholangitis decreased from 20% in 1986 to 4% in 2015 (P < 0.001). Primary biliary cholangitis was the only indication showing a consistent proportional decrease throughout all decades. From the first to the third decade, the age at liver transplantation increased from 54 (IQR 47‐59) to 56 years (IQR 48‐62) and the proportion of males increased from 11% to 15% (both P < 0.001). Conclusions: We have found a proportional decrease in primary biliary cholangitis as indication for liver transplantation. However, despite treatment with ursodeoxycholic acid and improved disease awareness, the absolute annual number of liver transplantations has stabilised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malinchoc, M., Kamath, P. S., Gordon, F. D., Peine, C. J., Rank, J., & ter Borg, P. C. J. (2000) · Hepatology · doi:10.1053/he.2000.5852 · Cited by 2,893 · cited 2×
“Data collected for our primary analyses included date of birth, gender, date of listing for liver transplantation, date of liver transplantation, and the biochemical parameters used to calculate the model for end‐ stage liver disease (MELD) score at the time of transplantation.(18) Indications for liver transplantatio…”
MethodHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 3×
“Table 2 shows the biochemical response for these UDCA‐treated patients according to the Barcelona, Paris I, and GLOBE response criteria.(14,20,24,25) In this cohort of transplanted patients with PBC, 6‐47% of patients showed a biochemical response to treatment, depending on the response criteria.”
BackgroundMethodChazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 2×
“Table 2 shows the biochemical response for these UDCA‐treated patients according to the Barcelona, Paris I, and GLOBE response criteria.(14,20,24,25) In this cohort of transplanted patients with PBC, 6‐47% of patients showed a biochemical response to treatment, depending on the response criteria.”
MethodEpidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.025 · Cited by 632
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498 · cited 1×
“The biochemical disease stage was determined based on serum albumin and bilirubin concentrations according to the Rotterdam criteria, classifying PBC into early (normal total bilirubin and normal albumin), moderately advanced (abnormal total bilirubin or abnormal albumin), or advanced disease (abnormal total bilirubin…”
MethodSelf-citationLammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441 · cited 2×
“However, with a median age at diagnosis of 46 years in patients with PBC listed for transplantation within our in‐depth population, this population undergoing liver transplantation for PBC was much younger at diagnosis than the large overall cohorts reported by the Global PBC Study Group (55 years) and the UK‐PBC Stud…”
MethodResultSelf-citation
Cited by
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Recent advances in clinical practice: Epidemiology of autoimmune liver diseases
Trivedi, P. J., & Hirschfield, G. M. (2021) · Gut · doi:10.1136/gutjnl-2020-322362 · Cited by 244
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17755 · Cited by 39
Harms, M. H., Hirschfield, G. M., Floreani, A., Mayo, M. J., Parés, A., Liberman, A., Malecha, E. S., Pencek, R., MacConell, L., & Hansen, B. E. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2020.100191 · Cited by 17
Self-citation
Metadata
- Authors
- Harms, M. H., Janssen, Q. P., Adam, R., Duvoux, C., Mirza, D., Hidalgo, E., Watson, C., Wigmore, S. J., Pinzani, M., Isoniemi, H., Pratschke, J., Zieniewicz, K., Klempnauer, J. L., Bennet, W., Karam, V., van Buuren, H. R., Hansen, B. E., Metselaar, H. J., & the European Liver and Intestine Transplant Association (ELITA)
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2018-12-18
- Volume
- 49
- Issue
- 3
- Pages
- 285-295
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2905002724
- Cited by
- 56
- References
- 19
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. https://app.cochat.ai/papers/10.1111/apt.15060
- The paper
- Harms, M. H., Janssen, Q. P., Adam, R., Duvoux, C., Mirza, D., Hidalgo, E., Watson, C., Wigmore, S. J., Pinzani, M., Isoniemi, H., Pratschke, J., Zieniewicz, K., Klempnauer, J. L., Bennet, W., Karam, V., van Buuren, H. R., Hansen, B. E., Metselaar, H. J., & the European Liver and Intestine Transplant Association (ELITA). (2019). Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.15060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.